PH94B Nasal Spray + Placebo Nasal Spray

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Social Anxiety Disorder

Conditions

Social Anxiety Disorder

Trial Timeline

Aug 30, 2021 → Aug 16, 2022

NCT ID

NCT05011396

About PH94B Nasal Spray + Placebo Nasal Spray

PH94B Nasal Spray + Placebo Nasal Spray is a phase 3 stage product being developed by Vistagen Therapeutics for Social Anxiety Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05011396. Target conditions include Social Anxiety Disorder.

What happened to similar drugs?

7 of 15 similar drugs in Social Anxiety Disorder were approved

Approved (7) Terminated (3) Active (6)

✅Cariprazine + PlaceboAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅quetiapineAstraZenecaApproved

✅Pristiq + PlaceboPfizerApproved

✅Sertraline + PlaceboPfizerApproved

✅NefazodoneBristol Myers SquibbApproved

✅EscitalopramLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05011396	Phase 3	Terminated	Aug 30, 2021	Aug 16, 2022	Social Anxiety Disorder
NCT04754802	Phase 3	Completed	May 24, 2021	Jun 22, 2022	Social Anxiety Disorder

Competing Products

20 competing products in Social Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
LY686017 + paroxetine + placebo	Eli Lilly	Phase 2	35
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Cariprazine + Placebo	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
quetiapine	AstraZeneca	Phase 3	32
quetiapine	AstraZeneca	Phase 2/3	38
Seroquel + Sugar Pill	AstraZeneca	Phase 3	40
quetiapine	AstraZeneca	Approved	43
Pristiq + Placebo	Pfizer	Approved	43
Venlafaxine ER	Pfizer	Phase 3	40
Ziprasidone + Sertraline	Pfizer	Phase 2	35
Sertraline + Placebo	Pfizer	Approved	35
Nefazodone	Bristol Myers Squibb	Approved	43
Escitalopram	Lundbeck	Approved	40
Cipralex + Placebo	Lundbeck	Phase 2	32
BHV-0223 + Placebo	Biohaven	Phase 2/3	32
VQW-765 + Placebo	Vanda Pharmaceuticals	Phase 3	37
PH94B	Vistagen Therapeutics	Phase 3	22
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray	Vistagen Therapeutics	Phase 2	32